STOCK TITAN

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Ironwood Pharmaceuticals (NASDAQ: IRWD) will conduct its fourth quarter and full year 2022 investor update conference call on February 16, 2023, at 8:30 a.m. Eastern Time. Interested participants can join by dialing (888) 330-2384 for the U.S. and Canada, or (240) 789-2701 for international calls, using conference ID 4671230. The call will be accessible for replay starting the same day at 11:30 a.m. Eastern Time until March 2, 2023. Ironwood specializes in gastrointestinal healthcare and is known for its leading product, LINZESS®, aimed at treating IBS-C and CIC.

Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 16, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting Thursday, February 16, 2023 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, March 2, 2023. To listen to the replay, dial (800) 770-2030 (U.S. and Canada) or (647) 362-9199 (international) using conference ID number 4671230. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.

About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.

Investors:

Greg Martini, 617-374-5230

gmartini@ironwoodpharma.com

Matt Roache, 617-621-8395

mroache@ironwoodpharma.com

Media:

Beth Calitri, 978-417-2031

bcalitri@ironwoodpharma.com

Source: Ironwood Pharmaceuticals, Inc.

FAQ

What date will Ironwood Pharmaceuticals host its Q4 2022 investor update call?

Ironwood Pharmaceuticals will host its Q4 2022 investor update call on February 16, 2023.

What time does Ironwood Pharmaceuticals' investor update call start?

The investor update call starts at 8:30 a.m. Eastern Time.

How can I participate in the Ironwood Pharmaceuticals conference call?

To participate, dial (888) 330-2384 for the U.S. and Canada or (240) 789-2701 internationally, using conference ID 4671230.

When will the replay of the Ironwood Pharmaceuticals investor call be available?

The replay will be available starting February 16, 2023, at 11:30 a.m. Eastern Time until March 2, 2023.

What is the main product of Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals is known for LINZESS®, a treatment for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Ironwood Pharmaceuticals, Inc. -

NASDAQ:IRWD

IRWD Rankings

IRWD Latest News

IRWD Stock Data

718.11M
157.19M
1.68%
105.28%
5.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
BOSTON